Get started
Author

D. Espinoza

Observed names: D Espinoza, David e Espinoza
ORCID: 0009-0000-1874-4145
Observed ORCID: 0009-0000-1874-4145
OpenAlex ID: A5084542003
The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial
2020 · William O Tarnow-Mordi, Mohamed E Abdel-Latif, et al. · The Lancet Child & Adolescent Health · 54
PDF
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
2015 · A. Davidson, A.-S. Veillard, et al. · Annals of Oncology · 34
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease
2014 · R V Seimon, D Espinoza, et al. · International Journal of Obesity · 30
A systematic review and meta-analysis of utility estimates in melanoma
2017 · A.D. Tran, G. Fogarty, et al. · British Journal of Dermatology · 22
Parent-focused behavioural interventions for the prevention of early childhood obesity (TOPCHILD): a systematic review and individual participant data meta-analysis
2025 · Kylie E Hunter, David Nguyen, et al. · The Lancet · 20
Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?
2017 · A.K. Smit, L.A. Keogh, et al. · British Journal of Dermatology · 18
Quantifying the advantages of conducting a prospective meta-analysis (PMA): a case study of early childhood obesity prevention
2021 · A. L. Seidler, K. E. Hunter, et al. · Trials · 17
PDF
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma
2015 · I.D. Davis, A. Long, et al. · Annals of Oncology · 14
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial
2014 · R V Seimon, D Espinoza, et al. · International Journal of Obesity · 8
An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study
2020 · K. Vuong, B.K. Armstrong, et al. · British Journal of Dermatology · 4
623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12
2024 · F.P. Lin, A. Mersiades, et al. · Annals of Oncology · 2
PDF
2715P Phase II trial of tildrakizumab in treatment-refractory bone and soft tissue sarcomas
2025 · M. Kansara, F.P. Lin, et al. · Annals of Oncology · 1
636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
2024 · B.Y. Kong, F.P-Y. Lin, et al. · Annals of Oncology
PDF
212P Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
2020 · G.T. Quah, D. Espinoza, et al. · Annals of Oncology
PDF
213P Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
2020 · G.T. Quah, D. Espinoza, et al. · Annals of Oncology
PDF
P0211 EVERSUN: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (ANZUP Trial 0901)
2014 · I.D. Davis, A. Long, et al. · European Journal of Cancer
Works count: 16
Citation count: 224
H-index: 8
I10-index: 8
Year
Topic
Type